BD's Q2 Revenues Rise 4 Percent | GenomeWeb

NEW YORK (GenomeWeb News) – Becton Dickinson said today that its fiscal second-quarter revenues rose nearly 4 percent year over year, beating analyst estimates.

For the quarter ended March 31, 2012, BD posted $1.99 billion in revenues, up from $1.92 billion for the second quarter of 2011, outpacing analysts' consensus estimate of $1.94 billion.

Revenue from the firm's BD Diagnostics segment was up 4 percent to $630 million, compared to $605 million a year ago. Growth was driven primarily by the preanalytical systems unit and women's health and cancer, the company said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.

Clinicians look to fold non-medical data into algorithms to predict patients' health, the Wall Street Journal reports.

Connecticut's biotech investment is leading to the building of labs to house new startups, the Associated Press reports.

Craig Venter's Health Nucleus aims to change preventive medicine, according to the Robb Report.